| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9fb7bbc09927d64558e1e99a3b7c719b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-72 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0781
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-002 |
| filingDate |
2016-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_913289e551aaa25b84a1b7767a28aed8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b57458d13594472c27c7f339af568e9a |
| publicationDate |
2020-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10688171-B2 |
| titleOfInvention |
Chlamydia-activated B cell platforms and methods thereof |
| abstract |
Disclosed herein is a Chlamydia-activated B cell (CAB) platform. Also disclosed is a method of enhancing a population of B cells, comprising exposing said B cells to Chlamydia spp. under conditions suitable to enhance the population of B cells, such that expansion and differentiation of said B cells takes place, and said B cells are exposed or crosslinked to an antigen. Also disclosed are methods of producing said CABs, and treating a subject in need thereof with said CABs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11253582-B2 |
| priorityDate |
2015-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |